Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics.
Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics.
复制标题
呼吸道合胞病毒（RSV）感染的炎症反应和免疫调节药物治疗的发展。
DOI：
10.2174/092986712799828346
复制
发表时间：
2012
影响因子：
4.1
通讯作者：
Domachowske JB
中科院分区：
文献类型：
--
作者：
Rosenberg HF;Domachowske JB
呼吸道合胞病毒（RSV；副粘病毒科，肺炎病毒属）是婴幼儿和儿童的主要呼吸道病原体，也是老年人的新兴病原体。目前RSV疾病的管理包括对确定为高风险的婴儿进行单克隆抗体预防，并对活动性感染的婴儿进行支持性护理；目前还没有疫苗，尽管有几种正在研究中。在这篇论文中，我们回顾了已发表的人体尸检研究结果，以及对急性肺炎病毒感染的人类临床样本和小鼠模型的实验，这些实验阐明了疾病发病机制的基本原理。考虑到这些数据表明，对RSV和相关肺炎病毒病原体的炎症反应可能是强烈的、持续的，并且超出了常规抗病毒和抗炎治疗的控制，并且可能对宿主产生深远的负面影响。从这个角度来看，我们考虑的情况下，特定的免疫调节策略，可能有减轻这种疾病的一些更严重的后遗症的潜力。
Respiratory syncytial virus (RSV; Family Paramyxoviridae, Genus Pneumovirus) is a major respiratory pathogen of infants and children and an emerging pathogen of the elderly. Current management of RSV disease includes monoclonal antibody prophylaxis for infants identified as high risk and supportive care for those with active infection; there is no vaccine, although several are under study. In this manuscript, we review published findings from human autopsy studies, as well as experiments that focus on human clinical samples and mouse models of acute pneumovirus infection that elucidate basic principles of disease pathogenesis. Consideration of these data suggests that the inflammatory responses to RSV and related pneumovirus pathogens can be strong, persistent, and beyond the control of conventional antiviral and anti-inflammatory therapies, and can have profound negative consequences to the host. From this perspective, we consider the case for specific immunomodulatory strategies that may have the potential to alleviate some of the more serious sequelae of this disease.